This is the authors' abstract. We don't add key points for this paper.
Unlike in the USA and Europe, dipeptidyl peptidase-4 inhibitor is the most prescribed first-line medication for type 2 diabetes patients in Japan, while there is a wide variation in the drug choice by facility-type and prefecture.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bouchi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: